U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H18N3O10.Zn.3H
Molecular Weight 456.74
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTETATE ZINC

SMILES

[H+].[H+].[H+].[Zn++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O

InChI

InChIKey=UVJDUBUJJFBKLD-UHFFFAOYSA-L
InChI=1S/C14H23N3O10.Zn/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);/q;+2/p-2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H
Molecular Weight 1.0079
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H18N3O10
Molecular Weight 388.3068
Charge -5
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.federalregister.gov/articles/2011/08/19/2011-21227/determination-that-pentetate-calcium-trisodium-trisodium-calcium-diethylenetriaminepentaacetate

Pentetate calcium trisodium is also known as trisodium calcium diethylenetriaminepentaacetate and is commonly referred to as Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. It is a white, water-soluble solid. It has a molecular formula of Na3CaC14H18N3O10 and a molecular weight of 497.4 Daltons. Ca-DTPA is supplied as a clear, colorless, hyperosmolar (1260 mOsmol/kg) solution in a colorless ampoule containing 5 mL. The ampoule contents are sterile, non-pyrogenic and suitable for intravenous administration. Each mL of solution contains the equivalent of 200 mg pentetate calcium trisodium (obtained from 158.17 mg pentetic acid, 40.24 mg calcium carbonate and NaOH) in water for injection, USP. The pH of the solution is adjusted with NaOH and is between 7.3 - 8.3. Ca-DTPA forms stable chelates with metal ions by exchanging calcium for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Ca-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in the deposition of these elements in tissues including the bone. The Food and Drug Administration (FDA) has determined that PENTETATE CALCIUM TRISODIUM (trisodium calcium diethylenetriaminepentaacetate (Ca-DTPA)) solution for intravenous or inhalation administration, equivalent to (EQ) 1 gram (g) base/5 milliliters (mL) (EQ 200 milligrams (mg) base/mL) was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PENTETATE CALCIUM TRISODIUM (Ca-DTPA) solution for intravenous or inhalation administration (EQ 1 g base/5 mL (EQ 200 mg base/mL)), if all other legal and regulatory requirements are met. Ca-DTPA treatments are not expected to be effective for uranium and neptunium. Radioactive iodine is not bound by DTPA

Originator

Curator's Comment: Akorn licensed Ca-DTPA and Zn-DTPA from Hameln Pharmaceuticals gmbh in October 2004.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Inactive ingredient
DermaKlear Akne Treatment with Sulfur

Approved Use

Uses for the treatment of acne. Dries acne blemishes and allows skin to heal. Helps prevent new acne blemishes from forming.

Launch Date

1940
Diagnostic
PENTETATE CALCIUM TRISODIUM

Approved Use

Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Launch Date

2004
Palliative
PENTETATE ZINC TRISODIUM

Approved Use

Pentetate zinc trisodium injection is a radiomitigation chelator indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.6 nM
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.007 nM × h
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.53 h
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 g 1 times / day multiple, subcutaneous (starting)
Dose: 0.5 g, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.5 g, 1 times / day
Co-administed with::
Zinc sulphate(200 mg two to five times daily)
Sources:
unhealthy, 5-20 years)
n = 5
Health Status: unhealthy
Condition: homozygous beta thalassaemia
Age Group: 5-20 years)
Sex: M+F
Population Size: 5
Sources:
4 g 1 times / day multiple, intramuscular
Overdose
Dose: 4 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy
Other AEs: Hemochromatosis...
Other AEs:
Hemochromatosis (grade 5, 3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hemochromatosis grade 5, 3 patients
4 g 1 times / day multiple, intramuscular
Overdose
Dose: 4 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
Role of S-adenosyl-L-methionine in potentiating cadmium mobilization by diethylenetriamine penta acetic acid in mice.
2001
In vitro evaluation of intravascular stent artifacts in three-dimensional MR angiography.
2001 Apr
Prediction rule for characterization of hepatic lesions revealed on MR imaging: estimation of malignancy.
2001 Apr
A cream containing the chelator DTPA (diethylenetriaminepenta-acetic acid) can prevent contact allergic reactions to metals.
2001 Apr
Bilaminar pattern of tibial condyle cartilage layer on the fat-suppressed 3D gradient echo images: artifact or structural and biochemical difference in composition of cartilage?
2001 Feb
Early retardation of 99mTc-DTPA radioaerosol transalveolar clearance in irradiated canine lung.
2001 Feb
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
2001 Feb
Clearance of Tc-99m DTPA aerosol in mismatched and matched pulmonary perfusion defects.
2001 Feb
[The scintigraphy of somatostatin receptors in the carcinoid tumor].
2001 Feb
Inhibitors of advanced glycation end product-associated protein cross-linking.
2001 Feb 14
Metal chelators inhibit S-nitrosation of Cys beta 93 in oxyhemoglobin.
2001 Feb 28
Images in clinical medicine. Captopril-augmented renal scan.
2001 Feb 8
Potential 166Ho radiopharmaceuticals for endovascular radionuclide therapy. II. Preparation and evaluation of 166Ho-DTPA.
2001 Jan
Seizures in multiple sclerosis.
2001 Jan
Somatostatin receptor imaging: current status and future perspectives.
2001 Jul
Lanthanide chemistry with (bis[[bis(carboxymethyl)amino]methyl]phosphinate: what does an extra phosphinate group do to EDTA?
2001 Jul 16
Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains.
2001 Jul-Aug
In vivo evaluation of 111In-DTPA-N-TIMP-2 in Kaposi sarcoma associated with HIV infection.
2001 Jun
Zinc-induced activation of the human cytomegalovirus major immediate-early promoter is mediated by metallothionein and nuclear factor-kappaB.
2001 Jun 15
The kinetics and mechanisms of the reactions of aluminium(III) with gallic acid, gallic acid methyl ester and adrenaline.
2001 Mar
3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties.
2001 Mar
Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction.
2001 Mar
Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas.
2001 Mar
A novel view of pH titration in biomolecules.
2001 Mar 27
Synthesis, characterization, and relaxivity of two linear Gd(DTPA)-polymer conjugates.
2001 Mar-Apr
Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In.
2001 May
Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.
2001 May 15
Patents

Sample Use Guides

Rats: The acute oral LD(50) of Pentasodium Pentetate in rats was > 5 g/kg. The acute dermal LD(50) of Pentapotassium Pentetate using rats was reported to be > 2 g/kg. The intraperitonal LD(50) of Pentetic Acid was reported to be 585 mg/kg.
Route of Administration: Other
Approximately 0.1 ml of solution of Ca-DTPA (pentetate calcium trisodium) was added to the test cultures (human lymphocytes) at 3 different concentrations: 0.77, 0.077, and 0.0077 mg/ml, resulting in a final concentration in the culture medium of 13.51, 1.351, and 0.135 ug/ml, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:20:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:20:37 GMT 2023
Record UNII
828I5G7VJ6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTETATE ZINC
Common Name English
ZINCATE(3-), (N,N-BIS(2-(((CARBOXY-.KAPPA.O)METHYL)(CARBOXYMETHYL)AMINO-.KAPPA.N)ETHYL)GLYCINATO(5-)-.KAPPA.N,.KAPPA.O)-, HYDROGEN (1:3)
Systematic Name English
ZNDTPA
Common Name English
ZINC, (((CARBOXYMETHYLIMINO)BIS(ETHYLENENITRILO))TETRAACETATO)-
Common Name English
GLYCINE, N,N-BIS(2-(BIS(CARBOXYMETHYL)AMINO)ETHYL)-, ZINC COMPLEX
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C62357
Created by admin on Fri Dec 15 15:20:37 GMT 2023 , Edited by admin on Fri Dec 15 15:20:37 GMT 2023
Code System Code Type Description
PUBCHEM
152703
Created by admin on Fri Dec 15 15:20:37 GMT 2023 , Edited by admin on Fri Dec 15 15:20:37 GMT 2023
PRIMARY
NCI_THESAURUS
C120570
Created by admin on Fri Dec 15 15:20:37 GMT 2023 , Edited by admin on Fri Dec 15 15:20:37 GMT 2023
PRIMARY
FDA UNII
828I5G7VJ6
Created by admin on Fri Dec 15 15:20:37 GMT 2023 , Edited by admin on Fri Dec 15 15:20:37 GMT 2023
PRIMARY
CAS
65229-17-6
Created by admin on Fri Dec 15 15:20:37 GMT 2023 , Edited by admin on Fri Dec 15 15:20:37 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE